chufangao/CTO huggingface dataset:
Clinical trial NCT04051203: Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia
Official title: Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-01
Primary completion date: 2023-12-01
Completion date: 2023-12-01
Plan to share individual participant data: NO
IPD sharing description: There is no plan, all participant data will be kept on a secured REDCap database.
Clinical trial NCT04431466: A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19
Official title: Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)
Acronym: IFORS
Sponsor: Universidade Federal de Sao Carlos (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Preliminary data from a pilot study suggest that the administration of ivermectin in patients with SARS-CoV-2 is safe, reducing symptoms and viral load. The antiviral effects of ivermectin appear to depend on the dose administered.
Enrollment: 32.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-07-01
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Plan to share individual participant data: NO
Clinical trial NCT04738292: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Official title: A Phase II Trial of OnapriStone in CoMbInation With FuLvestrant for Patients With ER-positive, and HER2-negative Metastatic Breast Cancer After Progression on Endocrine Therapy and CDK 4/6 Inhibitors
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: funding
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-05
Primary completion date: 2023-04-03
Completion date: 2023-05-15
Limitations and caveats: Study was terminated early, sponsor closed study. Study not powered per protocol.
Plan to share individual participant data: NO
Clinical trial NCT04395105: Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial
Official title: High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial
Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Low rate of recruitment
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-21
Primary completion date: 2021-04-05
Completion date: 2021-05-21
Plan to share individual participant data: NO
Clinical trial NCT06087731: Efficacy and Safety of Tocilizumab for TAO
Official title: Efficacy and Safety of Tocilizumab for Patients With Thyroid-associated Ophthalmopathy
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: For some personal reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-09-23
Primary completion date: 2023-09-23
Completion date: 2023-09-23
Plan to share individual participant data: NO
Clinical trial NCT04811131: Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
Official title: A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 114.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-04
Primary completion date: 2021-08-09
Completion date: 2021-08-09
Baseline population: The Baseline Analysis Population is based on all treated participants.
Plan to share individual participant data: NO
Clinical trial NCT04982575: Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Official title: Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-02
Primary completion date: 2022-07-07
Completion date: 2022-07-07
Baseline population: Full analyis set (FAS) included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04810208: Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
Official title: A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
Sponsor: Lidds AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic decision
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-28
Primary completion date: 2021-10-07
Completion date: 2021-10-07
Clinical trial NCT02867813: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Official title: A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease
Acronym: FOURIER OLE
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 5035.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-02
Primary completion date: 2022-03-21
Completion date: 2022-03-21
Baseline population: The Overall Number of Baseline Participants is made up of all of the participants that received study drug.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT02514239: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients
Official title: An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 13.0
Start date: 2015-07-08
Primary completion date: 2018-07-17
Completion date: 2020-07-02
Baseline population: Treated set (TS): all patients who were administered trial medication.
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Clinical trial NCT02765997: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Official title: Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy
Sponsor: Masonic Cancer Center, University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: IRB Disapproval
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-30
Primary completion date: 2020-06-30
Completion date: 2022-06-30
Clinical trial NCT01131169: Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Official title: A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-05-31
Primary completion date: 2020-05-15
Completion date: 2020-05-15
Clinical trial NCT03866577: Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
Official title: A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Sponsor: Momenta Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was terminated based on Sponsor decision.
Enrollment: 50.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-12-21
Primary completion date: 2021-06-09
Completion date: 2021-06-09
Limitations and caveats: Part C (Group 2) and Part D were planned but not conducted based on sponsor decision to discontinue the study after completion of Part A, Part B, and Part C (Group 1). No safety concerns were identified and study was terminated for business reasons.
Plan to share individual participant data: NO
Clinical trial NCT02060305: Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
Official title: A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
Sponsor: National Taiwan University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Very slow enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-02-01
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT04396106: Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19
Sponsor: Atea Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study closed out early due to evolving COVID-19 standard of care
Enrollment: 83.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-05-26
Primary completion date: 2022-01-10
Completion date: 2022-02-28
Baseline population: Intent-to-treat
Limitations and caveats: Study was prematurely discontinued. At the time of study discontinuation, only 2 subjects were enrolled in Part B and both received placebo.
Clinical trial NCT03590210: Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
Official title: NiTraSarc Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas - The NiTraSarc Phase II Trial
Acronym: NiTraSarc
Sponsor: University Medicine Greifswald (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-08
Primary completion date: 2022-02-12
Completion date: 2022-02-12
Plan to share individual participant data: NO
Clinical trial NCT03730402: Laparoscopic Assisted Plane Block (LAPB) Trial
Official title: Laparoscopic Assisted Plane Block (LAPB) Trial: Bupivacaine Versus Liposomal Bupivacaine Versus Standard Local Anesthesia for Post-operative Analgesia
Sponsor: Santa Barbara Cottage Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: There were not enough attendings/residents working on the study throughout the COVID-19 pandemic in order to enroll the number of patients required to meet statistical significance.
Enrollment: 34.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-04
Primary completion date: 2021-04-14
Completion date: 2021-04-14
Plan to share individual participant data: NO
Clinical trial NCT02524275: Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Official title: Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low enrollment
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-03-30
Primary completion date: 2021-10-28
Completion date: 2021-10-28
Clinical trial NCT06160609: Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
Official title: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5. Sub-study 1 - Belantamab Mafodotin and aOX40 (GSK3174998) in Combination
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to lack of efficacy.
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-07
Primary completion date: 2023-01-09
Completion date: 2023-01-09
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT02832687: Multi-dose Acetaminophen for Patients Undergoing General Anesthesia
Official title: A Multi-center, Randomized, Double-blind, Pilot Study on the Effect of Intravenous Multi-dose Acetaminophen on Readiness for Discharge in Patients Undergoing Surgery With General Anesthesia
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was halted due to the worldwide COVID-19 pandemic and the cancellation of all elective cases.
Enrollment: 88.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-19
Primary completion date: 2020-09-01
Completion date: 2020-12-31
Baseline population: A total of 88 patients were enrolled; from 47 who were randomized to receive intravenous acetaminophen 45 completed the study; from 41 received placebo 41 completed. A total of 65 patients were included into analyses with 34 receiving intravenous acetaminophen and 31 receiving placebo.
Plan to share individual participant data: NO
Clinical trial NCT03850483: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Official title: A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 344.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-04-08
Primary completion date: 2021-04-20
Completion date: 2021-04-20
Baseline population: Analysis population included participants who were randomly assigned to PF-06700841 and applied at least 1 dose of PF-06700841.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04537078: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders
Official title: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders
Sponsor: El Shatby University Hospital for Obstetrics and Gynecology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 90.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2021-03-01
Completion date: 2021-09-01
Plan to share individual participant data: NO
Clinical trial NCT02570789: Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
Official title: A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Acronym: METASUN
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: not enough accrual
Enrollment: 90.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-12-31
Primary completion date: 2018-12-31
Completion date: 2021-03-01
Clinical trial NCT03745989: Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
Official title: Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumors
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-22
Primary completion date: 2021-03-19
Completion date: 2021-03-19
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03136497: A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Official title: Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Sponsor: Hackensack Meridian Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-05
Primary completion date: 2020-11-09
Completion date: 2020-11-09
Baseline population: 10 patients consented, of which 9 were treated and 1 screen failure
Plan to share individual participant data: NO
Clinical trial NCT03825783: A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
Official title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene.
Sponsor: Rocket Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Patients were enrolled under global Phase 1/2 protocol RP-L201-0318.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-15
Primary completion date: 2021-10-31
Completion date: 2021-10-31
Clinical trial NCT03057990: Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)
Official title: A Phase 1 Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Intermediate/ High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or is Refractory to Azanucleosides
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study never opened; closed on 06/29/2021 due to no enrllment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-11
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Plan to share individual participant data: NO
Clinical trial NCT04028349: ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)
Official title: An Open-label, Single Arm Study to Provide Additional Information on Immunogenicity and Safety of Ad26.ZEBOV/MVA-BN-Filo
Sponsor: MRC/UVRI and LSHTM Uganda Research Unit (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 800.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-01
Primary completion date: 2021-03-19
Completion date: 2021-03-19
Plan to share individual participant data: NO
Clinical trial NCT04447040: Acetaminophen/Naproxen Sodium Dose Ranging Study
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Five Strengths of a Fixed Combination of Acetaminophen/Naproxen Sodium in Postoperative Dental Pain
Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 304.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-11-09
Primary completion date: 2021-04-09
Completion date: 2021-05-03
Plan to share individual participant data: YES
IPD sharing description: Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.